Objective To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral venous pressure (EVP) in normal dogs. Methods Normotensive beagle dogs were randomized to receive Bimatoprost SR 30 lg (n = 7) or sham injection (needle insertion only, n = 7) in one eye on day 1. EVP was measured with an episcleral venomanometer through day 65. Episcleral aqueous outflow vessels were identified using fluorescence imaging following intracameral injection of indocyanine green in one additional animal. A separate cohort of dogs that had been trained for conscious intraocular pressure (IOP) measurements received Bimatoprost SR 30 lg (n = 8) in one eye; IOP was evaluated through day 66. Results Baseline mean EVP was 10.0 mmHg in the Bimatoprost SR group and 10.4 mmHg in the sham group. Eyes treated with Bimatoprost SR exhibited a transient increase in mean EVP that peaked at day 8, followed by a decrease to levels below baseline. From day 29 to day 65, the change in mean EVP from baseline ranged from À2.4 to À3.9 mmHg (P < 0.05 vs. sham). Baseline mean IOP in eyes treated with Bimatoprost SR was 14.9 mmHg, and a steady IOP reduction was maintained through day 66. Bimatoprost SR-treated eyes exhibited a selective, sustained dilation of aqueous outflow vessels that was not observed in sham-treated eyes. Conclusions In normal dogs, Bimatoprost SR was associated with a transient increase in EVP followed by a sustained decrease. Changes in EVP were accompanied by a sustained dilation of aqueous outflow vessels.
INTRODUCTION
Aqueous humor outflow ultimately drains into the systemic circulation via the episcleral vasculature. 1 Consequently, episcleral venous pressure (EVP) is an important determinant of intraocular pressure (IOP) as expressed by the modified Goldmann equation: IOP = EVP + (Q-U)Ä C, where Q is aqueous humor production, U is uveoscleral outflow, and C is outflow facility. 1, 2 Given that in normal dogs EVP has been reported to be in the range of 11.4-11.6 mmHg 3 and IOP to average 19 mmHg across various breeds, 4 EVP accounts for approximately 60% of IOP in dogs. Furthermore, elevated EVP, either idiopathic or associated with Sturge-Weber syndrome, is associated with increased IOP and glaucoma. [5] [6] [7] Several studies in humans suggested that EVP was unaffected by topical ocular hypotensive medications such as carbonic anhydrase inhibitors, 8 beta-blockers, [8] [9] [10] [11] or prostaglandin analogs (PGAs). 10, 12 As a result, EVP generally has been assumed to remain constant, has rarely been measured, and has not been considered a promising target of IOP-lowering therapy. We recently demonstrated, however, that topical latanoprost produces statistically significant increases in EVP in normal dogs. 13 During 29 days of dosing with latanoprost 0.005% once daily, the mean increase in EVP ranged from 2.2 to 5.3 mmHg, with a maximal increase of 55%. 13 Nevertheless, there was a net reduction of IOP likely due to increased uveoscleral outflow and trabecular outflow facility also associated with a topical PGA. 14, 15 The change in EVP with a topical PGA was an important finding because the normal dog is commonly used in glaucoma research. If EVP is more dynamic and sensitive than previously thought, our understanding of aqueous dynamics and the effects of topical ocular hypotensive therapy on these fluid dynamics may be incomplete. A bimatoprost sustained-release intracameral implant (Bimatoprost SR) is currently in development for the treatment of open-angle glaucoma. Bimatoprost SR is a rod-shaped implant sized to fit within the intracameral space 16 and contains the PGA bimatoprost in the NOVA-DUR (Allergan plc, Dublin, Ireland) biodegradable, solid polymer drug delivery system. 17 The implant is designed to slowly release the drug over a period of 4 to 6 months. Similar to topical bimatoprost, 18 Bimatoprost SR does not have a contralateral effect on IOP (Allergan, Data on File). The primary purpose of this study was to evaluate the effect of Bimatoprost SR on EVP in normal dogs.
MATERIALS A ND ME THODS
Twenty-three normal female beagle dogs were included in this study. The study was performed at Covance Laboratories in Madison, Wisconsin under an approved Animal Care and Use Committee protocol. All procedures were in compliance with Animal Welfare Act Regulations (9 CFR 3), and routine veterinary care was performed in accordance with the ARVO Guidelines for Use of Animals in Ophthalmic and Visual Research, Animal Welfare Act, the National Research Council Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.
A total of 15 animals (seven for EVP measurements and eight for IOP measurements) were treated with a single Bimatoprost SR 30 lg implant in one eye only on study day 1. Each animal was lightly sedated, and immediately prior to dosing with Bimatoprost SR, the study eye was anesthetized with topical proparacaine hydrochloride 0.5%. Povidone-iodine 5% eye drops were applied preoperatively for 2 minutes and rinsed with balanced salt solution. A lid speculum was placed, and the eye was visualized through an operating microscope. Bimatoprost SR was injected into the anterior chamber using a singleuse applicator equipped with a 27-gauge needle. The needle was introduced just anterior to the insertion of the conjunctiva at the limbus through the clear cornea in the superior temporal quadrant using counter-traction with a toothed forceps lightly grasping the conjunctiva near the limbus. Topical gatifloxacin 0.3% eye drops were applied postoperatively.
The control group for EVP measurements consisted of seven animals treated with a sham injection. These animals were prepared using the same procedures as the animals in the active treatment group, but received only a needle stick in the study eye with the single-use Bimatoprost SR applicator. The purpose of this control arm was to assess the effect of needle entry into the anterior chamber on EVP.
Following the treatment with Bimatoprost SR or sham injection, EVP was measured noninvasively on study days 8, 11, 15, 22, 29, 36, 49 , and 65 using an episcleral venomanometer (model EV-310l, Eye Tech Ltd, Morton Grove, IL, USA) mounted on a slit lamp while the animal was under general anesthesia, as described previously. 13 The venomanometer is similar in design to a Goldmann tonometer. The silicone tip of the instrument is placed in contact with the ocular surface over the episcleral vasculature, and pressure exerted is gradually increased with a dial on the side of the venomanometer until the targeted vessel is 50% blanched. An episcleral aqueous outflow vessel approximately 3 mm from the limbus was identified for EVP measurement, and the median of three readings was used for analysis. The EVP measurement was performed in a masked fashion using a two-person technique while dogs were maintained in a sternal position. Throughout the study, an ACVO board-certified veterinary ophthalmologist (P.E.M.), who did not look at the pressure on the dial, performed the episcleral vessel applanation procedure, and a second person recorded the pressure in mmHg.
To verify that the episcleral vessels running perpendicular to the limbus in the dog eye were the aqueous outflow vessels, 10 lL of indocyanine green (ICG; 2.5 mg/mL) was injected intracamerally into both eyes of one additional animal. Episcleral vasculature was imaged with the confocal scanning laser ophthalmoscopic feature of the Spectralis HRA+OCT (Heidelberg Engineering, Germany).
The effects of Bimatoprost SR on IOP were measured in eight dogs who had been preconditioned for conscious IOP measurement (without systemic or topical anesthesia) by Covance technicians for 8 weeks prior to treatment with Bimatoprost SR. This eliminated potentially confounding effects of anesthetic agents on IOP measurements. 19 Intraocular pressure was measured using a TonoVet rebound tonometer (Paragon Medical, Coral Springs, FL, USA) while dogs were maintained in a sternal position, consistent with the positioning used with the EVP measurements. Following the administration of Bimatoprost SR on study day 1, IOP measurements were taken on day 3 or 4, and every 2 to 5 days thereafter through day 66.
Statistical methods
Sample size calculations determined that six dogs per group would provide a precision of AE2.4 mmHg (half the width of the 95% confidence interval) to estimate the mean difference in EVP change from baseline between the Bimatoprost SR group and the sham group. The calculations assumed that EVP follows a normal distribution with a common standard deviation of 1.9 mmHg for EVP change from baseline in both the Bimatoprost SR and sham groups. 13 An additional 1-2 animals per group were included to ensure that at least six dogs per group would complete the study.
Summary statistics of EVP and IOP were calculated at baseline and on each study day. The mixed model repeated measures (MMRM) method 20 was used to analyze the EVP data. In the model, the EVP was the response variable, the group (Bimatoprost SR or sham), study day, and group-by-day interaction were treated as fixed effects, and the animal and animal-by-day interaction were treated as random effects. After the model was fit, the fixed effects were tested, and comparisons between Bimatoprost SR-and sham-treated eyes at baseline and each study day were made. P values <0.05 were considered statistically significant.
RE SUL TS
Putative aqueous outflow vessels used for EVP measurements in this study were identified anatomically by fluorescence imaging of the episclera following ICG injection into the anterior chamber of both eyes of a representative dog (Fig. 1) . Following the ICG injection, the outflow vessels that fluoresced were long and straight, emanated from the limbus for at least 4 mm posteriorly, were separated by approximately 1 clock hour, and were nonmobile when the overlying conjunctiva was manipulated with a cotton-tipped applicator. Figure 2 illustrates the changes in mean EVP in eyes treated with Bimatoprost SR or sham. At baseline, mean EVP was 10.0 mmHg in the Bimatoprost SR group and 10.4 mmHg in the sham group. After treatment, shamtreated eyes maintained a relatively steady EVP (mean of 9.2 mmHg) throughout the study. In eyes treated with Bimatoprost SR, there was a biphasic change in EVP, with an early, transient increase peaking at day 8 followed by a decrease in EVP to levels sustained below baseline. The mean decrease in EVP from baseline from day 29 through day 65 ranged from 2.4 to 3.9 mmHg and was statistically significant compared with sham (P < 0.05, Fig. 2) .
In eyes treated with Bimatoprost SR for IOP measurements, the mean IOP at baseline was 14.9 mmHg. After administration of Bimatoprost SR, the mean IOP decreased rapidly, ranging from 10.0 mmHg to 10.6 mmHg at 2-3 days post-treatment. A substantial decrease in IOP from baseline was sustained through study day 66 (Fig. 3) . The average change in IOP from baseline through day 66 was -3.1 mmHg. Following the administration of Bimatoprost SR, the episcleral aqueous outflow vessels appeared to dilate (Fig. 4a) . This vasodilation was sustained throughout the study period. There were no changes in the clinical appearance of the episcleral aqueous outflow vessels in sham-treated eyes (Fig. 4b) .
DISCUSSION
Intracameral dosing with Bimatoprost SR had a biphasic effect on EVP in normal dogs. This effect was characterized by an early, transient increase in EVP within the first 2 weeks post-treatment, followed by a sustained decrease in EVP lasting from 4 weeks to at least 7 weeks posttreatment. Changes in EVP in sham-treated animals were small, indicating that the effect of Bimatoprost SR on EVP was not due to needle entry into the anterior chamber. A separate cohort of animals treated with Bimatoprost SR exhibited a decrease in IOP that was sustained through at least 7 weeks post-treatment.
The reduction in EVP after Bimatoprost SR administration is in contrast to the increase in EVP that was measured during dosing with the topical PGA latanoprost 0.005% in our earlier published study in normal beagle dogs (bred and evaluated at the same facility as in this study). 13 These results suggest that intracameral delivery of a PGA using Bimatoprost SR may have a unique effect on EVP not possible with topical PGA dosing. The specialized anatomy and functionality of the episcleral vasculature may help explain the differences in the changes in EVP produced by topical and intracameral PGA dosing. In various species including rabbits, dogs, and humans, the episcleral vasculature communicating with the aqueous drainage from the anterior chamber is characterized by a lack of capillaries and a plethora of arteriovenous anastomoses that allow complex hemodynamics of the episcleral arterioles and venules. [21] [22] [23] [24] In addition, the episcleral vasculature is highly muscular and richly innervated with vasodilative and vasoconstrictive nerves. 24 It has been suggested that this complex anatomy may allow regulation of blood flow and volume in the episcleral vessels, with subsequent effects on EVP, aqueous outflow facility, and IOP. 22, 24 During topical PGA application, all episcleral vessels would be exposed to drug, and subsequent generalized vasodilation (seen clinically as hyperemia) 25 could potentially shift blood flow from the arterial to the venous side of the episcleral circulation through the arteriovenous anastomoses. This type of generalized episcleral vasodilation has been shown to lead to an increase in both EVP and IOP in a rabbit in vivo model. 22 Conversely, intracameral PGA delivery via Bimatoprost SR would result in drug exposure confined to the episcleral outflow vessels, selective vasodilation of the episcleral veins, and a decrease in EVP (Fig. 5) . This hypothesis is supported by the observation in this study that Bimatoprost SR treatment was associated with a selective vasodilation of episcleral aqueous outflow vessels rather than the more general vasodilation of ocular surface vessels typical of topically applied PGAs. The different effects of topical PGAs and Bimatoprost SR on EVP suggest that Bimatoprost SR may be able to decrease IOP via an additional mechanism not available to topically applied PGAs. Topical PGAs are highly efficacious ocular hypotensive agents because they facilitate aqueous outflow. The increase in outflow with topical PGAs is generally believed to occur through the uveoscleral and trabecular pathways. 26, 27 Nonetheless, there are limits to the ocular hypotensive effects of topical PGAs, and increasing dose frequency beyond once daily, or combining 2 drugs from this same class, results in a decrease in ocular hypotensive efficacy. [28] [29] [30] If Bimatoprost SR can access an additional mechanism of IOP lowering through its effect on EVP, it may be possible for this therapy to overcome the IOP-lowering limitations of topical PGA therapy. A preclinical study in cynomolgus monkeys, which showed that Bimatoprost SR can provide significant additional IOP lowering when added to topical bimatoprost, suggests that this may indeed be the case. 31 A limitation of this study is that the EVP measurements were conducted under general anesthesia, and the potential effects of anesthesia on EVP are not known. As the same anesthetic methods were used in all animals, however, anesthesia is unlikely to account for the different changes in EVP in the Bimatoprost SR-and sham-treated groups. In addition, the clinical applicability of these results may be limited because the aqueous drainage mechanism in the dog is slightly different from humans and nonhuman primates. Dogs do not have a true Schlemm's canal, but they do have a condensed venous plexus, which drains into aqueous outflow vessels that are structurally similar to those seen in humans. 21 The use of a needle stick as a sham, instead of a sham implant containing polymer only, is a limitation as the effect of an implant not containing drug on IOP and EVP was not specifically evaluated in this study. Lastly, we have discussed the changes in EVP with Bimatoprost SR in comparison with those seen in our previously published paper on the changes in EVP with topical latanoprost. 13 Topical latanoprost is considered by regulatory agencies to be in the same PGA class as bimatoprost and have a similar mechanism of action. 32 Nevertheless, as we did not evaluate the effects of topical vs. intracameral bimatoprost on EVP in a head-to-head study, we cannot definitively conclude that the effects of these bimatoprost delivery modalities on EVP are different.
In summary, we demonstrated that intracameral PGA delivery with Bimatoprost SR in normal dogs was associated with a transient increase in EVP followed by a sustained decrease. These findings suggest that EVP should not be considered to be constant in studies of aqueous fluid dynamics in these animals. The modified Goldmann equation indicates that EVP is an important determinant of IOP so, if it can be modulated, it could be an important target for future ocular hypotensive therapies. Further mechanism of action studies are needed to determine whether the observations in this animal study translate to humans.
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